Durable response to crizotinib in metastatic angiomatoid fibrous histiocytoma with EWSR1–CREB1 fusion and ALK overexpression

C. Ngo; T. Grinda; A. Boilève; A. Levy; C. Le Pechoux; L. Haddag; A. Valent; T. Lazure; S. Briand; C. Honoré; M. Faron; O. Mir; R. Bahleda; B. Verret; A. Le Cesne

doi:10.1016/j.annonc.2022.05.003

Durable response to crizotinib in metastatic angiomatoid fibrous histiocytoma with EWSR1–CREB1 fusion and ALK overexpression

C. Ngo, T. Grinda, A. Boilève, A. Levy, C. Le Pechoux, L. Haddag, A. Valent, T. Lazure, S. Briand, C. Honoré, M. Faron, O. Mir, R. Bahleda, B. Verret, A. Le Cesne

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

5 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	848-850
Nombre de pages	3
journal	Annals of Oncology
Volume	33
Numéro de publication	8
Les DOIs	https://doi.org/10.1016/j.annonc.2022.05.003
état	Publié - 1 août 2022

Accès au document

10.1016/j.annonc.2022.05.003

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Ngo, C., Grinda, T., Boilève, A., Levy, A., Le Pechoux, C., Haddag, L., Valent, A., Lazure, T., Briand, S., Honoré, C., Faron, M., Mir, O., Bahleda, R., Verret, B., & Le Cesne, A. (2022). Durable response to crizotinib in metastatic angiomatoid fibrous histiocytoma with EWSR1–CREB1 fusion and ALK overexpression. Annals of Oncology, 33(8), 848-850. https://doi.org/10.1016/j.annonc.2022.05.003

@article{da7e31ad08a1452ca9e2a6f53ad10843,

title = "Durable response to crizotinib in metastatic angiomatoid fibrous histiocytoma with EWSR1–CREB1 fusion and ALK overexpression",

author = "C. Ngo and T. Grinda and A. Boil{\`e}ve and A. Levy and {Le Pechoux}, C. and L. Haddag and A. Valent and T. Lazure and S. Briand and C. Honor{\'e} and M. Faron and O. Mir and R. Bahleda and B. Verret and {Le Cesne}, A.",

note = "Funding Information: None declared. ALC: honoraria from Bayer, Pharmamar, Decipher. BV: consultancy fees from Novartis, Pfizer, Netcancer, Lilly, Fabre, Seagen, Gilead; non-financial support (travel paid) from Lilly, Novartis, Pfizer, Accord Healthcare, Amgen. AB: non-financial support (accommodation paid) from IPSEN. OM: consultancy fees from AstraZeneca, Amgen, Bayer, Blueprint Medicines, BMS, Eli-Lilly, Ipsen, Janssen, Lundbeck, MSD, Novartis, Roche, Pfizer, Servier, Vifor Pharma; honoraria from Blueprint Medicines, Roche, Pfizer, Servier; support for attending meeting and/or travel from Amgen, Roche, Pfizer, PharmaMar; stock ownership from Amgen, Amplitude Surgical, Ipsen, Transgene. AV: honoraria from AstraZeneca. All other authors have declared no conflicts of interest.",

year = "2022",

month = aug,

day = "1",

doi = "10.1016/j.annonc.2022.05.003",

language = "English",

volume = "33",

pages = "848--850",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "8",

}

Ngo, C, Grinda, T, Boilève, A, Levy, A, Le Pechoux, C, Haddag, L, Valent, A, Lazure, T, Briand, S, Honoré, C, Faron, M, Mir, O, Bahleda, R, Verret, B & Le Cesne, A 2022, 'Durable response to crizotinib in metastatic angiomatoid fibrous histiocytoma with EWSR1–CREB1 fusion and ALK overexpression', Annals of Oncology, VOL. 33, Numéro 8, p. 848-850. https://doi.org/10.1016/j.annonc.2022.05.003

TY - JOUR

T1 - Durable response to crizotinib in metastatic angiomatoid fibrous histiocytoma with EWSR1–CREB1 fusion and ALK overexpression

AU - Ngo, C.

AU - Grinda, T.

AU - Boilève, A.

AU - Levy, A.

AU - Le Pechoux, C.

AU - Haddag, L.

AU - Valent, A.

AU - Lazure, T.

AU - Briand, S.

AU - Honoré, C.

AU - Faron, M.

AU - Mir, O.

AU - Bahleda, R.

AU - Verret, B.

AU - Le Cesne, A.

N1 - Funding Information: None declared. ALC: honoraria from Bayer, Pharmamar, Decipher. BV: consultancy fees from Novartis, Pfizer, Netcancer, Lilly, Fabre, Seagen, Gilead; non-financial support (travel paid) from Lilly, Novartis, Pfizer, Accord Healthcare, Amgen. AB: non-financial support (accommodation paid) from IPSEN. OM: consultancy fees from AstraZeneca, Amgen, Bayer, Blueprint Medicines, BMS, Eli-Lilly, Ipsen, Janssen, Lundbeck, MSD, Novartis, Roche, Pfizer, Servier, Vifor Pharma; honoraria from Blueprint Medicines, Roche, Pfizer, Servier; support for attending meeting and/or travel from Amgen, Roche, Pfizer, PharmaMar; stock ownership from Amgen, Amplitude Surgical, Ipsen, Transgene. AV: honoraria from AstraZeneca. All other authors have declared no conflicts of interest.

PY - 2022/8/1

Y1 - 2022/8/1

UR - http://www.scopus.com/inward/record.url?scp=85135118310&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2022.05.003

DO - 10.1016/j.annonc.2022.05.003

M3 - Letter

C2 - 35568279

AN - SCOPUS:85135118310

SN - 0923-7534

VL - 33

SP - 848

EP - 850

JO - Annals of Oncology

JF - Annals of Oncology

IS - 8

ER -